



RNS Number : 9557A

Integrated Diagnostics Holdings PLC

07 June 2021

## **Integrated Diagnostics Holdings PLC**

**07 June 2021**

THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION

### **Change of Auditor**

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Company" or "the Group"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, announces that it has been notified by KPMG LLP ("KPMG") that KPMG will not be seeking reappointment as auditor of the Company when their present term of office expires at the forthcoming Annual General Meeting of the Company.

The Company is also delighted to announce that PwC has indicated its willingness to be appointed as the Company's auditor, subject to the satisfactory completion of their acceptance procedures, which is expected to become effective upon agreement by shareholders at the Company's Annual General Meeting to be held on 30th June 2021.

In accordance with paragraph (9) of Article 113B of the Companies (Jersey) Law 1991, KPMG has deposited with the Company a statement setting out the reasons for not seeking reappointment. A copy of KPMG's statutory statement is available on this [link](#) and will be sent to every member of the Company and to every person entitled to receive notice of general meetings today as required under paragraph (10) of Article 113B of the Companies (Jersey) Law 1991.

The Board of Directors of IDH ("the Board") has engaged with KPMG to ensure it understands their position. The Board notes that KPMG has provided an unqualified audit opinion on the Company's FY2020 accounts and in every year of the preceding five years.

The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.

#### **Contact**

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | [nancy.fahmy@idhcorp.com](mailto:nancy.fahmy@idhcorp.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPUPUWAQUPGPUQ